Our top pick for
Cortexyme, Inc is a biotechnology business based in the US. Cortexyme shares (CRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Cortexyme employs 23 staff and has a market cap (total outstanding shares value) of USD$1.5 billion.
Since the stock market crash in March caused by coronavirus, Cortexyme's share price has had significant negative movement.
Its last market close was USD$51.41, which is 14.43% down on its pre-crash value of USD$60.08 and 83.41% up on the lowest point reached during the March crash when the shares fell as low as USD$28.03.
If you had bought USD$1,000 worth of Cortexyme shares at the start of February 2020, those shares would have been worth USD$812.01 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,069.84.
|Latest market close||USD$51.41|
|52-week range||USD$20.14 - USD$73.84|
|50-day moving average||USD$49.4462|
|200-day moving average||USD$46.038|
|Wall St. target price||USD$78.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.169|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||-9.70%|
|1 month (2020-10-30)||7.40%|
|3 months (2020-08-28)||17.78%|
|6 months (2020-05-29)||11.54%|
|1 year (2019-11-29)||95.85%|
|2 years (2018-11-26)||N/A|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-20.57%|
|Return on equity TTM||-33.38%|
|Market capitalisation||USD$1.5 billion|
TTM: trailing 12 months
There are currently 1.7 million Cortexyme shares held short by investors – that's known as Cortexyme's "short interest". This figure is 7.2% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Cortexyme shares can be evaluated.
Cortexyme's "short interest ratio" (SIR) is the quantity of Cortexyme shares currently shorted divided by the average quantity of Cortexyme shares traded daily (recently around 143262.60720412). Cortexyme's SIR currently stands at 11.66. In other words for every 100,000 Cortexyme shares traded daily on the market, roughly 11660 shares are currently held short.
However Cortexyme's short interest can also be evaluated against the total number of Cortexyme shares, or, against the total number of tradable Cortexyme shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cortexyme's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Cortexyme shares in existence, roughly 60 shares are currently held short) or 0.1082% of the tradable shares (for every 100,000 tradable Cortexyme shares, roughly 108 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cortexyme.
Find out more about how you can short Cortexyme stock.
We're not expecting Cortexyme to pay a dividend over the next 12 months.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.